Solodyn Antitrust Settlement
PLEASE NOTE: THE FILING DEADLINE TO SUBMIT A CLAIM TO THIS SETTLEMENT HAS PASSED. MCAG WILL UPDATE CLIENTS ACCORDINGLY ONCE INFORMATION IS AVAILABLE ON DISTRIBUTIONS FROM THIS SETTLEMENT.
In re: Solodyn (Minocycline Hydrochloride) Antitrust Litigation, MDL No. 2503
Settlement Fund: $43,000,000
Settlement Period: July 23, 2009 – February 25, 2018
Claim Filing Deadline: July 31, 2018
There are currently a number of active antitrust settlements and lawsuits that fall into the category of “pharmaceutical settlements.” Under these settlements, it is generally alleged that businesses with self-insured health plans overpaid for drugs purchased on behalf of their employees due to artificially inflated and/or stabilized prices. The prices were allegedly manipulated as a result of anticompetitive practices undertaken by the drug manufacturers.
This lawsuit claims that the Defendants violated state competition (i.e. antitrust and consumer protection) and unjust enrichment laws by agreeing not to compete with each other and keeping lower-cost generic versions of Solodyn off the market.
Organizations that have a self-insured benefits plan are eligible if, as a third-party payor, the plan, at any time from July 23, 2009 to February 25, 2018, purchased, paid and/or reimbursed for some or all of the purchase price for 45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg, and/or 135mg Solodyn and/or its generic versions of one or more of these dosages. Purchases could have been for employees, insureds, participants, or beneficiaries covered under your benefits plan.
To be eligible, the transaction must have taken place in any of the following locations:
- Alabama, Alaska, Arizona, Arkansas, California, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, Washington, West Virginia, Wisconsin, Wyoming, the District of Columbia and Puerto Rico
Next Steps for MCAG Clients
Data is often required to complete your claim for settlements in this category. MCAG can quickly review the process with you so we can easily obtain necessary information from your Pharmacy Benefit Manager (i.e. CVS Caremark, Express Scripts, OptumRX) to pursue current and future pharmaceutical settlements. Should you wish to proceed, please contact an Account Manager at 800.355.0466 or send an email to email@example.com.